Molecular Profile Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Profile Name ARID1A Q758Rfs*75
Gene Variant Detail

ARID1A Q758Rfs*75 (loss of function - predicted)

Relevant Treatment Approaches EZH2 inhibitor


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ARID1A Y551Lfs*72 ARID1A Q758Rfs*75 ovarian cancer sensitive Olaparib + Temozolomide Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Lynparza (olaparib) and Temodar (temozolomide) synergistically inhibited viability of an ovarian cancer cell line harboring ARID1A Y551Lfs*72 and Q758Rfs*75 in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37306706). 37306706